Case-control study finds MMP7 promoter polymorphism not a risk factor for endometriosis in eastern Indian women, highlighting severe disease susceptibility.
Introduction: Matrix metalloproteinase-7 (MMP7) regulates pathogenesis of endometriosis by promoting cellular invasion and extracellular matrix remodeling. The present study aimed to understand whether single nucleotide polymorphism (SNP) of MMP7 promoter region at −181A/G can be a risk factor for development of endometriosis in eastern Indian population. Methods: The case-control cohort included 130 women with endometriosis and 130 women without endometriosis from East Indian population. Polymorphism of MMP7 (rs11568818) at −181A/G was genotyped by polymerase chain reaction-restriction enzyme length polymorphism. Results: Our study did not identify MMP7 −181A > G promoter polymorphism as a risk factor for increased incidences of endometriosis. However, endometriosis patients having AG and AG + GG (pooled) genotypes showed increased susceptibility for developing severe endometriosis ( p = 0.0485, OR: 2.864, 95% CI: 0.979–8.372 and p = 0.0428 OR: 2.848, 95% CI: 1.010–8.031 respectively) as compared to AA genotype. Endometriosis patients with GG genotype have faster disease development (5.65 ± 4.40 years, p = 0.0215) as compared to the endometriosis patients with AA genotype (8.71 ± 5.25 years). Conclusions: Promoter polymorphism of MMP7 (−181A > G) is not a risk factor for increased incidences of endometriosis in eastern Indian women. However, endometriosis patients with MMP7 -181G genotypes are susceptible to faster disease progression and developing severe endometriosis.
No takes yet. Share an insight, caveat, or question.
Chatterjee et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: